valvookimakaj1362.blogspot.com
Life sciences and technology investorSafeguard (NYSE:SFE) said the gain and an increasre in shareholders’ equity will be recognizer in the current quarter ending June 30. A private placementy with reduced Safeguard’s share in Clarient (NASDAQ:CLRT) from abouyt 50 percent to about47 percent. Safeguard Presidentr and CEO Peter J. Boni said the deal “noy only strengthened our balance sheet andfinancial flexibility, but the valued of Safeguard’s ongoing stake in Clarient can now be more readiluy understood by the investment Safeguard said the market value of its remainingb holdings is about $123 million as of Wednesday.
Clarient provide anatomic pathology and molecular testingt servicesto pathologists, oncologists and the pharmaceuticak industry. It’s based in Alisok Viejo, Calif.
Nenhum comentário:
Postar um comentário